OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ARCI56

Archit Organosys Ltd

Commodity ChemicalsVerified

Archit Organosys Ltd has a debt-to-equity ratio of 0.41, indicating a relatively conservative capital structure with a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 1.21, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess liquidity. The company's cash and equivalents amount to INR 3.97 million, which is significantly lower than its long-term debt of INR 264.45 million, resulting in a net cash position that is negative after subtracting total debt. In terms of profitability, the company's return on equity (ROE) is 2.79%, and its return on assets (ROA) is 1.65%. These figures are below the typical thresholds for strong performance in the Commodity Chemicals industry, indicating that the company is generating relatively modest returns on its equity and asset base. The operating margin, calculated as operating income divided by revenue, is 7.00%, which is in line with the industry median for commodity chemical producers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regional economic downturns or supply chain disruptions. Looking at the company's growth trajectory, the outlook for the current fiscal year indicates a modest increase in revenue, with a projected growth rate of less than 5%. The company's capital expenditures are negative, suggesting that it is not investing in new projects or expanding its production capacity, which may limit its long-term growth potential. The company's operating cash flow of INR 100.96 million provides some flexibility for reinvestment or debt reduction, but the absence of significant capital spending suggests a conservative approach to growth. The company's risk profile includes a medium liquidity risk, primarily due to its limited cash reserves relative to its debt obligations. The dilution risk is assessed as low, with no significant dilution events reported in the recent financial statements. The company's financial structure and operating performance suggest that it is not currently under pressure to issue new shares to fund operations or reduce debt, which supports the low dilution risk rating. Recent events, as disclosed in the company's financial filings, include a continuation of its focus on cost management and operational efficiency. The company has not reported any material changes in its business strategy or significant new projects in the latest financial period. The absence of major new developments suggests a stable but conservative business approach, with limited exposure to high-risk ventures or market expansion.

30-day price · ARCI+13.36 (+35.2%)
Low$36.34High$57.80Close$51.28As of17 May, 00:00 UTC
Profile
CompanyArchit Organosys Ltd
TickerARCI.BO
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Archit Organosys Ltd is a chemical manufacturing company that produces commodity chemicals and generates revenue primarily through the sale of chemical products.

Classification. Archit Organosys Ltd is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Archit Organosys Ltd has a debt-to-equity ratio of 0.41, indicating a relatively conservative capital structure with a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 1.21, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess liquidity. The company's cash and equivalents amount to INR 3.97 million, which is significantly lower than its long-term debt of INR 264.45 million, resulting in a net cash position that is negative after subtracting total debt. In terms of profitability, the company's return on equity (ROE) is 2.79%, and its return on assets (ROA) is 1.65%. These figures are below the typical thresholds for strong performance in the Commodity Chemicals industry, indicating that the company is generating relatively modest returns on its equity and asset base. The operating margin, calculated as operating income divided by revenue, is 7.00%, which is in line with the industry median for commodity chemical producers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regional economic downturns or supply chain disruptions. Looking at the company's growth trajectory, the outlook for the current fiscal year indicates a modest increase in revenue, with a projected growth rate of less than 5%. The company's capital expenditures are negative, suggesting that it is not investing in new projects or expanding its production capacity, which may limit its long-term growth potential. The company's operating cash flow of INR 100.96 million provides some flexibility for reinvestment or debt reduction, but the absence of significant capital spending suggests a conservative approach to growth. The company's risk profile includes a medium liquidity risk, primarily due to its limited cash reserves relative to its debt obligations. The dilution risk is assessed as low, with no significant dilution events reported in the recent financial statements. The company's financial structure and operating performance suggest that it is not currently under pressure to issue new shares to fund operations or reduce debt, which supports the low dilution risk rating. Recent events, as disclosed in the company's financial filings, include a continuation of its focus on cost management and operational efficiency. The company has not reported any material changes in its business strategy or significant new projects in the latest financial period. The absence of major new developments suggests a stable but conservative business approach, with limited exposure to high-risk ventures or market expansion.
Key takeaways
  • Archit Organosys Ltd has a conservative capital structure with a debt-to-equity ratio of 0.41, but its liquidity position is only medium due to limited cash reserves.
  • The company's profitability metrics, including a ROE of 2.79% and ROA of 1.65%, are below the typical thresholds for strong performance in the Commodity Chemicals industry.
  • The company's revenue is concentrated in a single business segment, with no material geographic diversification reported, which may increase its exposure to regional risks.
  • The company's growth trajectory is modest, with a projected revenue growth rate of less than 5% for the current fiscal year and no significant capital expenditures reported.
  • The company's risk profile includes a medium liquidity risk and a low dilution risk, with no significant dilution events reported in the recent financial statements.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's operating margin is expected to remain stable due to its focus on cost management and operational efficiency.
  • **rd_outlook_rationale**: The company is not currently investing in significant R&D projects, as indicated by the absence of material R&D expenditures in the financial statements.
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$309.9M
Gross profit$112.8M
Operating income$21.7M
Net income$17.9M
R&D
SG&A
D&A
SBC
Operating cash flow$101.0M
CapEx-$18.0M
Free cash flow
Total assets$1.08B
Total liabilities$440.9M
Total equity$641.5M
Cash & equivalents$4.0M
Long-term debt$264.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$945.1M$76.2M$50.1M$55.1M
FY-3$1.37B$124.3M$82.3M$10.5M
FY-2$1.28B$163.4M$113.6M-$12.7M
FY-1$1.13B-$13.0M$32.8M$61.5M
FY0$1.26B$70.3M$50.5M$105.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$874.9M$405.4M$38.1M
FY-3$1.04B$518.9M$53.5M
FY-2$1.20B$617.8M$3.6M
FY-1$1.08B$641.5M$4.0M
FY0$1.23B$692.1M$3.3M
PeriodOCFCapExFCFSBC
FY-4$111.1M-$31.6M$55.1M
FY-3$106.2M-$108.4M$10.5M
FY-2$172.4M-$160.2M-$12.7M
FY-1$101.0M-$18.0M$61.5M
FY0$185.2M-$5.0M$105.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$309.9M$21.7M$17.9M
FQ-6$270.0M$15.6M$10.1M
FQ-5$295.4M$13.5M$10.2M
FQ-4$258.7M$11.6M$10.1M
FQ-3$431.8M$29.5M$20.2M
FQ-2$332.0M$26.5M$20.4M
FQ-1$328.6M$11.9M$15.4M
FQ0$384.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.08B$641.5M$4.0M
FQ-6
FQ-5$1.18B$661.7M$3.1M
FQ-4
FQ-3$1.23B$692.1M$3.3M
FQ-2
FQ-1$1.24B$727.8M$4.4M
FQ0
PeriodOCFCapExFCFSBC
FQ-7$101.0M-$18.0M
FQ-6
FQ-5$36.3M
FQ-4
FQ-3$185.2M-$5.0M
FQ-2
FQ-1$34.4M-$6.9M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$641.5M
Net cash-$260.5M
Current ratio1.2
Debt/Equity0.4
ROA1.7%
ROE2.8%
Cash conversion5.6%
CapEx/Revenue-5.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricARCIActivity
Op margin7.0%5.5% medp25 -0.0% · p75 10.8%above median
Net margin5.8%4.1% medp25 0.1% · p75 8.8%above median
Gross margin36.4%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-5.8%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity41.0%37.1% medp25 10.3% · p75 82.0%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 01:43 UTC#712b1115
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 09:26 UTCJob: 3bdd2ae7